Twist Bioscience Corporation Common Stock (TWST) is a publicly traded Healthcare sector company. As of October 26, 2026, TWST trades at $141.15 with a market cap of $9.28B and a P/E ratio of -85.18. TWST moved +0.56% today. Year to date, TWST is +341.11%; over the trailing twelve months it is +339.58%. Its 52-week range spans $23.30 to $219.71. Analyst consensus is buy with an average price target of $158.10. Rallies surfaces TWST's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Leerink sees life-science tools benefiting from Anthropic's push into biology: Leerink Partners says Anthropic's growing focus on biology could boost demand for laboratory automation, experiments and data. The brokerage calls Twist Bioscience the “single most important beneficiary,” citing Anthropic-funded testing of 5,000 protein designs using Twist's synthetic DNA.
| Metric | Value |
|---|---|
| Price | $141.15 |
| Market Cap | $9.28B |
| P/E Ratio | -85.18 |
| EPS | $-2.22 |
| Dividend Yield | 0.00% |
| 52-Week High | $219.71 |
| 52-Week Low | $23.30 |
| Volume | 210.13K |
| Avg Volume | 0 |
| Revenue (TTM) | $431.80M |
| Net Income | $-136.72M |
| Gross Margin | 51.97% |
11 analysts cover TWST: 0 strong buy, 8 buy, 2 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $158.10.